Scholarlink

Background <p>The components of metabolic syndrome (MetS) have previously been demonstrated to be contributors to cognitive decline in older adults as individual factors, but not collectively as a syndrome. This study investigated whether adults ≥ 50&#xa0;years old who meet the criteria for MetS were more likely to develop impaired cognition than those without MetS.</p> Methods <p>Adults aged 50&#xa0;years or older without significant cognitive impairment who received outpatient care at Taipei Veterans General Hospital were recruited. Waist circumference, blood tests for Mets components, and high-sensitivity C-reactive protein (hsCRP) were measured. Demographics, health condition, cognitive function (by Montreal Cognitive Assessment Taiwanese version, MoCA-T, and AD-8), depression symptoms (by Geriatric Depression Scale-15) and functional status (by Barthel’s Index, and Lawton &amp; Brody instrumental activities of daily living, IADL) were evaluated. Associations between MetS&#xa0;and cognitive function were analyzed by multivariate logistic regression.</p> Results <p>Data of 567 participants were analyzed. The prevalence of MetS of the study population was 34.2%. MetS status was not significantly correlated to cognitive decline as indicated by Montreal Cognitive Assessment Taiwan version (<i>p</i> = 0.13) and AD-8 (<i>p</i> = 0.42). Mild abdominal obesity decreased the risk of developing impaired cognition in women (adjusted OR = 0.62, 95% CI = 0.42, 0.93, <i>p</i> = 0.02) but not in men (adjusted OR = 0.84, 95% CI = 0.46, 1.53, <i>p</i> = 0.58).</p> Conclusions <p>MetS is not a significant contributory factor to cognitive decline in community-dwelling middle-aged and older adults. An optimal waist circumference in community-dwelling older women is protective against the development of mild dementia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The association between metabolic syndrome components and cognitive function in community-dwelling middle-aged and older adults: the first wave result of a cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月29日

查看全文
  • Hsin-Yeong Yen,
  • Yi‑Hsuan Lin,
  • Yen-Feng Wang,
  • Jong-Ling Fuh,
  • Shuu-Jiun Wang,
  • Harn-Shen Chen,
  • Shu-Chiung Chiang,
  • Sih-Rong Li,
  • Ming-Hwai Lin,
  • Tzeng-Ji Chen,
  • Shinn-Jang Hwang,
  • Hsiao-Ting Chang

摘要

Background

The components of metabolic syndrome (MetS) have previously been demonstrated to be contributors to cognitive decline in older adults as individual factors, but not collectively as a syndrome. This study investigated whether adults ≥ 50 years old who meet the criteria for MetS were more likely to develop impaired cognition than those without MetS.

Methods

Adults aged 50 years or older without significant cognitive impairment who received outpatient care at Taipei Veterans General Hospital were recruited. Waist circumference, blood tests for Mets components, and high-sensitivity C-reactive protein (hsCRP) were measured. Demographics, health condition, cognitive function (by Montreal Cognitive Assessment Taiwanese version, MoCA-T, and AD-8), depression symptoms (by Geriatric Depression Scale-15) and functional status (by Barthel’s Index, and Lawton & Brody instrumental activities of daily living, IADL) were evaluated. Associations between MetS and cognitive function were analyzed by multivariate logistic regression.

Results

Data of 567 participants were analyzed. The prevalence of MetS of the study population was 34.2%. MetS status was not significantly correlated to cognitive decline as indicated by Montreal Cognitive Assessment Taiwan version (p = 0.13) and AD-8 (p = 0.42). Mild abdominal obesity decreased the risk of developing impaired cognition in women (adjusted OR = 0.62, 95% CI = 0.42, 0.93, p = 0.02) but not in men (adjusted OR = 0.84, 95% CI = 0.46, 1.53, p = 0.58).

Conclusions

MetS is not a significant contributory factor to cognitive decline in community-dwelling middle-aged and older adults. An optimal waist circumference in community-dwelling older women is protective against the development of mild dementia.